ProPhase Labs Inc (NASDAQ:PRPH) CEO Ted William Karkus sold 424,789 shares of ProPhase Labs stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $2.30, for a total transaction of $977,014.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Ted William Karkus also recently made the following trade(s):
- On Friday, September 29th, Ted William Karkus sold 364,950 shares of ProPhase Labs stock. The stock was sold at an average price of $2.30, for a total transaction of $839,385.00.
ProPhase Labs Inc (PRPH) opened at $2.15 on Thursday. ProPhase Labs Inc has a 1 year low of $1.78 and a 1 year high of $2.45. The company has a market cap of $26.60, a P/E ratio of 2.76 and a beta of 0.16.
ProPhase Labs declared that its Board of Directors has approved a share buyback plan on Friday, November 10th that authorizes the company to buyback 1,700,000 outstanding shares. This buyback authorization authorizes the company to repurchase shares of its stock through a tender offer. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
Separately, ValuEngine downgraded shares of ProPhase Labs from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th.
ProPhase Labs Company Profile
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.